S&P Global, Pearson, GE HealthCare Lead Week's Key Deals

Tempus AI is building a research platform based on 100,000 whole genomes linked to long term clinical records, a project that follows its $1.5 billion acquisition of Personalis. The Personalis deal strengthens Tempus' position in molecular residual disease testing, expanding the company from diagnosing and selecting cancer treatments into monitoring patients for cancer recurrence. The new whole genome project arrives after a sharp run in the shares, with a 90 day share price return of 62.68% and a 7 day gain of 31.91%, though the 1 year total shareholder return shows an 11.79% decline. Tempus AI closed at $77.84 against a narrative fair value estimate of $75.68, a level at which 26 investors see the stock as 3% overvalued. The company still carries ongoing losses and meaningful debt, so any setback integrating Personalis could quickly challenge the upbeat narrative.

Agilent Technologies launched the Agilent S540MD, a slide scanner that holds up to 540 glass slides at once, in the United States on September 4, following its January debut in select European markets. The FDA-cleared scanner is built for high-volume pathology labs preparing for AI-assisted workflows, can be refilled while running, fits standard racks, and uses automated scan modes and tissue detection; Majken Nielsen, who runs Agilent's Clinical Diagnostics Division, framed it as a way to tie digitization to customers' staining workflows. The launch lands alongside Agilent's August 26 report of $1.88 billion in revenue for the quarter ended July 31, up 8.1% from a year earlier, with non-GAAP earnings per share up 18%, and management raised full-year non-GAAP earnings guidance to $6.18 to $6.21 per share. The S540MD is a rebadged Hamamatsu NanoZoomer S540MD, and Agilent offered no pricing, unit targets, or revenue estimate for it. Tariff refunds added $0.06 to non-GAAP earnings per share and feed into the raised outlook, while the fourth-quarter guide assumes no further refunds and calls for core revenue growth of 5.2% to 6.2%, down from 7.3% in the third quarter.

Natera and its collaborators presented four abstracts at the IASLC 2026 World Conference on Lung Cancer, including the largest molecular residual disease dataset to date in resected stage 1–3 non-small cell lung cancer. The data showed that Signatera status after surgery is strongly associated with recurrence-free survival and overall survival, with Signatera-positive patients facing around five times the risk of recurrence or death during surveillance. The company said the results support broader use of MRD testing to guide post-surgical monitoring and treatment decisions in lung cancer care. The new dataset reinforces the clinical case for Signatera in resected NSCLC, though it does not clearly change the near-term financial catalyst, which remains Natera's push for broader coverage and usage of MRD testing. Natera has raised its 2026 revenue guidance to US$2.85 billion to US$2.91 billion, and its narrative projects $4.6 billion revenue and $449.9 million earnings by 2029, with a $344.33 fair value estimate implying a 7% downside to its current price.